For any new investors, the B-OM trial was chosen first because CTIX knew the antibacterial properties of B but wanted to ensure the effectiveness of the anticipated anti-inflammatory properties prior to commencing the UP trial. Otherwise it would have not been a smart choice with time and money to execute a trial to treat a condition (UP) which has symptoms of inflammation!!

Nice try fool, but do better next time. Actually, take your FUD elsewhere!!!